135 results match your criteria: "Dysautonomia Center[Affiliation]"

Background: Pain is a frequent yet poorly characterized symptom of multiple system atrophy (MSA). Understanding the factors influencing pain and its burden is crucial for improving the symptomatic treatment and quality of life of MSA individuals.

Objective: This study aimed at assessing the prevalence, characteristics, and current treatment strategies for pain in MSA.

View Article and Find Full Text PDF

An update on multiple system atrophy.

Curr Opin Neurol

August 2024

Dysautonomia Center, NYU Langone Health, NYU Grossman School of Medicine, New York, New York, USA.

Article Synopsis
  • Multiple system atrophy (MSA) is a serious neurological disorder marked by symptoms like autonomic failure, parkinsonism, and problems with coordination, primarily linked to α-synuclein protein issues.
  • Recent research suggests urinary infections may trigger α-synuclein aggregation, and updated diagnostic criteria improve early detection accuracy of the disease.
  • New diagnostic tools, including α-synuclein biomarkers from urine and brain scans, are being developed alongside clinical trials for various therapies aimed at slowing or reversing the disease's progression.
View Article and Find Full Text PDF

Dysautonomia and response to guanfacine in individuals with an SCN9A variant.

Clin Auton Res

April 2024

Department of Neurology, Dysautonomia Center and Autonomic Disorders Division, New York University Langone Health and New York University Grossman School of Medicine, 530 First Av, Suite 9Q, New York, NY, 10016, USA.

View Article and Find Full Text PDF

Muscarinic control of cardiovascular function in humans: a review of current clinical evidence.

Clin Auton Res

February 2024

Department of Neurology, NYU Dysautonomia Center, New York University School of Medicine, 530 First Av, Suite 9Q, New York, 10016, USA.

Article Synopsis
  • The review examines how muscarinic receptor modulation affects cardiovascular control in humans by summarizing data from clinical trials of new drug compounds.
  • It highlights the significance of positive allosteric modulators (PAMs) that target specific muscarinic receptor subtypes (M1-M5), which are in development for various conditions, including schizophrenia and Alzheimer's disease.
  • Despite variable results from existing clinical trials regarding heart rate and blood pressure control, understanding these mechanisms could lead to innovative treatments for cardiovascular issues.
View Article and Find Full Text PDF

Hereditary transthyretin (ATTRv; v for variant) amyloidosis is a rare, multisystem, progressive, and fatal disease in which polyneuropathy is a cardinal manifestation. Due to a lack of United States (US)-specific guidance on ATTRv amyloidosis with polyneuropathy, a panel of US-based expert clinicians convened to address identification, monitoring, and treatment of this disease. ATTRv amyloidosis with polyneuropathy should be suspected in unexplained progressive neuropathy, especially if associated with systemic symptoms or family history.

View Article and Find Full Text PDF

Background: Children with familial dysautonomia (FD) are smaller and grow more slowly than the general population. It is unknown whether this abnormal growth is due to comorbidities that patients with FD live with, or if it is a direct effect of the disease-causing homozygous ELP-1 mutations. Here, we created growth curves for weight, height, and body mass index (BMI) in male and female children with FD to monitor the nutritional status of patients with FD.

View Article and Find Full Text PDF

Familial dysautonomia.

Clin Auton Res

June 2023

Department of Neurology, Dysautonomia Center, New York University School of Medicine, New York, NY, USA.

Article Synopsis
  • - Familial dysautonomia (FD) is a genetic disorder primarily affecting individuals of Ashkenazi Jewish descent, leading to severe sensory loss and other autonomic dysfunctions due to a mutation in the ELP1 gene.
  • - Symptoms include extreme blood pressure fluctuations, respiratory issues from swallowing difficulties, and episodes of autonomic crises, leading to complications like blindness and impaired movement.
  • - Current treatments focus on managing symptoms, although new therapies targeting the underlying mutation are on the horizon, with early intervention seen as vital for effectiveness.
View Article and Find Full Text PDF
Article Synopsis
  • HSAN III, or familial dysautonomia, is a genetic disorder caused by an autosomal recessive mutation that leads to significant sensory neuron loss, impacting pain perception, temperature sensitivity, and proprioception.
  • Individuals with HSAN III exhibit absent stretch reflexes due to the lack of functional muscle spindle afferents, resulting in impaired proprioception, especially at the knee joint, which correlates with difficulties in walking.
  • While proprioception is normal at the elbow due to reliance on skin sensory cues, the absence of muscle spindles affects overall motor control, evidenced by poorer performance in tasks like the finger-to-nose test and Purdue pegboard compared to healthy peers.
View Article and Find Full Text PDF

Objective: Familial dysautonomia (FD) is a rare inherited autosomal recessive disorder with abnormal somatosensory, enteric, and afferent autonomic neurons. We aimed to define the incidence of gastrointestinal bleeding and its associated risk factors in patients with FD.

Methods: In this retrospective case-control study, we identified all episodes of gastrointestinal bleeding in patients with FD, occurring over four decades (January 1980-December 2017), using the New York University FD registry.

View Article and Find Full Text PDF

Early autonomic biomarkers in ATTRv carriers.

Clin Auton Res

February 2023

Department of Neurology, NYU Dysautonomia Center, New York University School of Medicine, 530 First Avenue, Suite 9Q, New York, NY, 1000, USA.

View Article and Find Full Text PDF
Article Synopsis
  • The Global Multiple System Atrophy Registry (GLOMSAR), created in 2013, is an online platform where patients or caregivers can self-report information about multiple system atrophy (MSA).
  • The study aimed to analyze the demographics of GLOMSAR participants and gather data from a symptom-focused online questionnaire, with 33% of the 1083 participants completing it.
  • Findings revealed that many symptoms, like memory issues and visual hallucinations, are commonly reported by patients but often overlooked in traditional physician studies, emphasizing the importance of patient experiences in MSA research.
View Article and Find Full Text PDF

Background: The second consensus criteria for the diagnosis of multiple system atrophy (MSA) are widely recognized as the reference standard for clinical research, but lack sensitivity to diagnose the disease at early stages.

Objective: To develop novel Movement Disorder Society (MDS) criteria for MSA diagnosis using an evidence-based and consensus-based methodology.

Methods: We identified shortcomings of the second consensus criteria for MSA diagnosis and conducted a systematic literature review to answer predefined questions on clinical presentation and diagnostic tools relevant for MSA diagnosis.

View Article and Find Full Text PDF

Different phenoconversion pathways in pure autonomic failure with versus without Lewy bodies.

Clin Auton Res

December 2021

Division of Autonomic Disorders, Department of Neurology, NYU Langone Health, NYU Dysautonomia Center, New York University Grossman School of Medicine, 530 First Avenue, Suite 9Q, New York, NY, 10016, USA.

Pure autonomic failure (PAF) is a rare disease in which chronic neurogenic orthostatic hypotension (nOH) dominates the clinical picture. Longitudinal studies have reported that PAF can phenoconvert to a central synucleinopathy with motor or cognitive involvement-i.e.

View Article and Find Full Text PDF

Purpose: In neurogenic orthostatic hypotension, blood pressure falls when upright owing to impaired release of norepinephrine, leading to dizziness. Ampreloxetine, a selective norepinephrine reuptake inhibitor, increases circulating norepinephrine levels. This study explored the safety of ampreloxetine and its effect on blood pressure and symptoms in patients with neurogenic orthostatic hypotension.

View Article and Find Full Text PDF

Autonomic failure: a neglected presentation of Parkinson's disease.

Lancet Neurol

October 2021

Dysautonomia Center, Division of Clinical Neurobiology, Department of Neurology, Medical University of Innsbruck, A-6020 Innsbruck, Austria; Laboratory of Translational Neurodegeneration Research, Division of Clinical Neurobiology, Department of Neurology, Medical University of Innsbruck, A-6020 Innsbruck, Austria.

View Article and Find Full Text PDF

Kurt Jellinger, Doyen of international neuropathology.

J Neural Transm (Vienna)

October 2021

Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Margarete Hoeppel-Platz 1, 97080, Wuerzburg, Germany.

View Article and Find Full Text PDF